Nevertheless, approximately one-fourth of patients using VEGF inhibitors will experience hypertension, while nearly every patient will exhibit significantly elevated blood pressure levels (Narayan et al., 2023; Pannucci et al., 2023). The gene discussed is VEGFA; the disease is hypertensive disorder.